BCTX 0.84 BriaCell Therapeutics Corp.
| Range: | 0.46-5.97 | Vol Avg: | 4728937 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 1.83 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Mar 14 2012 | Empoloyees: | 16 | ||
| CUSIP: | 10778Y302 | CIK: | 0001610820 | ISIN: | CA1079301091 | Country: | CA |
| CEO: | Dr. William V. Williams M.D. | Website: | https://www.briacell.com | ||||
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow